Moteur de recherche d’entreprises européennes
Financement de l’UE (8 689 222 €) : Interception précoce du diabète de type 2 à médiation inflammatoire Hor01/12/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Interception précoce du diabète de type 2 à médiation inflammatoire
The overall concept of INTERCEPT-T2D is to establish whether an inflammatory-mediated profile contributes to the onset of Type 2 Diabetes (T2D) complications, thus enabling the identification of patients most at risk of complications and the design of personalized prevention measures. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycemia and risk of chronic complications are so far difficult to predict. In this context, onset of diabetic complications represents the most important transitional phase of T2D development toward premature disability and mortality. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. INTERCEPT-T2D will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. The combination of state-of-the-art genomics and cell-biology technologies with targeted clinical interventions should lead to potent patients’ stratification. It should allow the identification and prognosis of a novel class or subclass of patients characterized by an “Inflammatory-mediated T2D” endotype. The project has access to the best-documented longitudinal human European cohorts of patients with T2D, with reliable clinical and biological data allowing to trace the transition and evolution towards organ complications. This, added to the exploitation of an extensive health data warehouse, will enable us to establish the inflammatory trajectory of citizens with T2D from diagnosis to the development of complications. To explore the ability to prevent the transition phase of T2D towards organ complications, INTERCEPT-T2D will conduct a phase II clinical trial with an anti-inflammatory therapy targeting NLRP3 Inflammasome activity in patients with T2D.
| Olatec Therapeutics B.V. | ? |
| Assistance Publique Hopitaux de Paris | 800 250 € |
| Centre Hospitalier Universitaire de Liege | 127 875 € |
| Deutsche Diabetes Forschungsgesellschaft e. V. | 1 369 397 € |
| Federation Francaise des Diabetiques | 74 188 € |
| Inserm Transfert SA | 400 375 € |
| Institut National de la Sante et de la Recherche Medicale | 3 038 108 € |
| Institut National de Recherche en Informatique et Automatique | 375 031 € |
| Karolinska Institutet | 568 125 € |
| Technische Universitaet Dresden | 965 750 € |
| Universita Degli Studi Di Verona | 430 000 € |
| Universite de la Reunion | 540 124 € |
https://cordis.europa.eu/project/id/101095433
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Olatec Therapeutics B.V., New York-FL, États-Unis.